Malignant pleural mesothelioma: a single-center experience in Turkey.
BACKGROUND
Malignant pleural mesothelioma is a rare lethal malignancy caused by asbestos exposure. It is more frequently seen in certain regions in Turkey. In this retrospective study, we aimed to analyse demographic, clinical, and pathological data and treatment-related features in 54 patients.


METHODS
The study included 54 patients diagnosed with malignant mesothelioma that were followed and treated.


RESULTS
Of the 54 patients, 34 (55.6%) were male. The median age in men and women were 60.3 (38.2-77.2) and 65.8 (37.7-77.5) years, respectively. In 35 (64.8%), exposure to asbestosis was present. Epithelial type was found in 27 (50.0%), followed by mixed type in 7 (13.0%) patients, and in 20 (37.0%) patients the subtype could not be determined. The disease was staged as IV in 37 (68.5%) patients. In 28 patients (51.9%), it was right-sided and in 1 (1.9%) it was bilateral. The most frequent metastatic sites (in decreasing order) were lungs, mediastinum, diaphragm, liver, and thoracal wall. Of the 54 patients, 36 (66.6%) received 1st-line chemotherapy and 20 (37%) 2nd-line chemotherapy. Eighteen patients (33.3%) received radiotherapy; 11 (20.3%) with palliative intention and 7 (12.9%) with curative intention. Median overall survival (OS) was 12.03 months (95% CI 7.2-16.8). OS was not affected by sex (p=0.32), smoking history (p=0.51), alcohol consumption (p=0.36), family history (p=0.67), pleural effusion presence (p=0.80), operation (p=0.14), clinical stage (p=0.072), symptom at presentation (p=0.66), having mixed type histology (p=0.079), asbestos exposure (p=0.06), and type of 1st-line chemotherapy (p=0.161). On the contrary, it may be positively affected by good ECOG PS (0-1) (p<0.01), age below 65 (p=0.03), left-sided disease (p=0.01), receiving chemotherapy (p<0.01), having unilateral pleural effusion (p=0.018), and type of 2nd-line chemotherapy (p=0.025).


CONCLUSIONS
OS of our patients was better than that found in the literature, seeming to be positively affected by early stages, better ECOG PS, age below 65 years, left side involvement, and having second-line chemotherapy with cisplatin-gemcitabine or 3M. Overall treatment success seems to be comparable to what is currently expected.
Department of Medical Oncology, Başkent University, Medical Faculty, Adana, Turkey.
Ahmet
A
Sezer
Department of Medical Oncology, Mustafa Kemal University, Medical Faculty, Hatay, Turkey.
Ahmet Taner
AT
Sümbül
Department of Medical Oncology, Başkent University, Medical Faculty, Adana, Turkey.
Hüseyin
H
Abalı
Department of Medical Oncology, Başkent University, Medical Faculty, Adana, Turkey.
Hüseyin
H
Mertsoylu
Department of Medical Oncology, Başkent University, Medical Faculty, Adana, Turkey.
Ozgür
O
Ozyılkan
D000328:Adult; D000368:Aged; D003710:Demography; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008654:Mesothelioma / Q000453:epidemiology* / Q000628:therapy; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000453:epidemiology* / Q000628:therapy; D014421:Turkey / Q000453:epidemiology